MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25–30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrach, S, Schmidt-Lauber, C, Pap, T, Pavenstädt, H, Schlatter, E, Schmidt, E, Berdel, W E, Schulze, U, Edemir, B, Jeromin, S, Haferlach, T, Ciarimboli, G, Bertrand, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056971/
https://www.ncbi.nlm.nih.gov/pubmed/27635733
http://dx.doi.org/10.1038/bcj.2016.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056971/
https://www.ncbi.nlm.nih.gov/pubmed/27635733
http://dx.doi.org/10.1038/bcj.2016.79

Ejemplares similares